Adam Binder, MD, discusses how to handle gastrointestinal toxicities for patients with relapsed/refractory multiple myeloma who are on the triple therapy of selinexor, bortezomib, and dexamethasone.
Adam Binder, MD
Adam Binder, MD, is an ssociate professor, associate director of inpatient operations, and quality office in the Division of Hematologic Malignancies at Thomas Jefferson University in Philadelphia, PA.
Articles by Adam Binder, MD
Adam Binder, MD, discusses what he found to be notable from the results of the phase 3 BOSTON trial that looked at the efficacy of selinexor, bortezomib, and dexamethasone triplet therapy for patients with relapsed/refractory multiple myeloma.